pharmafileMay 07, 2018
Tag: Free webinar , GVP , oncology medicines
It is timely to reflect on how we can best implement the revised GVP module (V) concerning risk management in the interests of patients throughout the life-cycle of a medicine.
Factors to consider include:
Taking into account the needs of the prescriber and other healthcare professionals
Applying the resources of the marketing authorisation holder (MAH) effectively to comply with regulatory expectation
Ensuring risk management plans reflect only measures that MAHs can reasonably control while retaining the MAH’s duty of care
Remembering risk management during clinical development is intrinsic to Good Clinical Practice
Providing precise instructions for minimising risk in the protocol and investigator brochure to form the basis of the EU risk management plan
Designing pivotal studies based on the anticipated target group once marketed
Defining recommended conditions for safe and effective use of a medicine to minimise risk
Thus, how can we now sensibly apply the revised GVP module for risk management?
This webinar will be conducted by an experienced ex-EU regulator who understands the detail by which a typical RMP will be assessed and who will provide practical guidance to help you produce compliant RMPs effectively and efficiently.
Click here to book your place today. If you require further information, please do not hesitate to contact us.
Our speaker for the event is Dr William Richardson, Medical Advisor at NDA Group.
Register as Visitor to CPhI China 2018!
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: